Next Article in Journal
NPM1-Mutated AML: Deciphering the Molecular and Clinical Puzzle in the Era of Novel Treatment Strategies
Previous Article in Journal
Correction: Gonzalez et al. Principles of Surgical Treatment of Soft Tissue Sarcomas. Cancers 2025, 17, 401
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 17
Issue 13
10.3390/cancers17132097
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Correction to Cancers 2024, 16(23), 4078.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Kwon, W.-A.; Lee, M.-K. Evolving Treatment Landscape of Frontline Therapy for Metastatic Urothelial Carcinoma: Current Insights and Future Perspectives. Cancers 2024, 16, 4078

by
Whi-An Kwon
1,* and
Min-Kyung Lee
2,*
1
Department of Urology, Myongji Hospital, Hanyang University College of Medicine, Goyang-si 10475, Republic of Korea
2
Department of Internal Medicine, Myongji Hospital, Hanyang University College of Medicine, Goyang-si 10475, Republic of Korea
*
Authors to whom correspondence should be addressed.
Cancers 2025, 17(13), 2097; https://doi.org/10.3390/cancers17132097
Submission received: 28 February 2025 / Revised: 22 April 2025 / Accepted: 6 June 2025 / Published: 23 June 2025
Browse Figures
Versions Notes

Error in Figure

In the original publication [1], there was a mistake in Figure 2b, where PD-1 and PD-L1 were switched. The corrected Figure 2 appears below. The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Kwon, W.-A.; Lee, M.-K. Evolving Treatment Landscape of Frontline Therapy for Metastatic Urothelial Carcinoma: Current Insights and Future Perspectives. Cancers 2024, 16, 4078. [Google Scholar] [CrossRef] [PubMed]
Cancers 17 02097 g002aCancers 17 02097 g002b
Figure 2. Drug classes and their mechanisms in the frontline treatment of metastatic urothelial carcinoma. (a) Platinum-based chemotherapy works by disrupting cell division. Platinum compounds bind to the DNA of cancer cells, creating cross-links that impede normal DNA replication and cell division. This DNA damage hampers the cancer cells’ growth and spread. (b) Immuno-therapy boosts the patient’s immune system to fight against cancer cells. It works by blocking immune checkpoint pathways, such as PD-1, PD-L1, and CTLA-4, which tumor cells use to evade immune detection. By inhibiting these pathways, immunotherapy enables the immune system to attack and eliminate cancer cells. (c) Antibody–drug conjugates (ADCs) consist of a cancer-specific antibody linked to a cytotoxic agent. Once the ADC attaches to the cancer cells, it is absorbed, and the toxic drug is released inside the cell, leading to cancer cell death. Enfortumab vedotin targets nectin-4, which is commonly overexpressed in urothelial cancer cells, while sacituzumab govitecan targets tumor cells through the anti-Trop-2 antibody. APC, antigen-presenting cell; CTLA-4, cyto-toxic T-lymphocyte associated protein 4; MMAE, monomethyl auristatin; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; PD-L2, programmed death-ligand 2; SN-38, 7-ethyl-10-hydroxycamptothecin.
Figure 2. Drug classes and their mechanisms in the frontline treatment of metastatic urothelial carcinoma. (a) Platinum-based chemotherapy works by disrupting cell division. Platinum compounds bind to the DNA of cancer cells, creating cross-links that impede normal DNA replication and cell division. This DNA damage hampers the cancer cells’ growth and spread. (b) Immuno-therapy boosts the patient’s immune system to fight against cancer cells. It works by blocking immune checkpoint pathways, such as PD-1, PD-L1, and CTLA-4, which tumor cells use to evade immune detection. By inhibiting these pathways, immunotherapy enables the immune system to attack and eliminate cancer cells. (c) Antibody–drug conjugates (ADCs) consist of a cancer-specific antibody linked to a cytotoxic agent. Once the ADC attaches to the cancer cells, it is absorbed, and the toxic drug is released inside the cell, leading to cancer cell death. Enfortumab vedotin targets nectin-4, which is commonly overexpressed in urothelial cancer cells, while sacituzumab govitecan targets tumor cells through the anti-Trop-2 antibody. APC, antigen-presenting cell; CTLA-4, cyto-toxic T-lymphocyte associated protein 4; MMAE, monomethyl auristatin; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; PD-L2, programmed death-ligand 2; SN-38, 7-ethyl-10-hydroxycamptothecin.
Cancers 17 02097 g002aCancers 17 02097 g002b
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Kwon, W.-A.; Lee, M.-K. Correction: Kwon, W.-A.; Lee, M.-K. Evolving Treatment Landscape of Frontline Therapy for Metastatic Urothelial Carcinoma: Current Insights and Future Perspectives. Cancers 2024, 16, 4078. Cancers 2025, 17, 2097. https://doi.org/10.3390/cancers17132097

AMA Style

Kwon W-A, Lee M-K. Correction: Kwon, W.-A.; Lee, M.-K. Evolving Treatment Landscape of Frontline Therapy for Metastatic Urothelial Carcinoma: Current Insights and Future Perspectives. Cancers 2024, 16, 4078. Cancers. 2025; 17(13):2097. https://doi.org/10.3390/cancers17132097

Chicago/Turabian Style

Kwon, Whi-An, and Min-Kyung Lee. 2025. "Correction: Kwon, W.-A.; Lee, M.-K. Evolving Treatment Landscape of Frontline Therapy for Metastatic Urothelial Carcinoma: Current Insights and Future Perspectives. Cancers 2024, 16, 4078" Cancers 17, no. 13: 2097. https://doi.org/10.3390/cancers17132097

APA Style

Kwon, W.-A., & Lee, M.-K. (2025). Correction: Kwon, W.-A.; Lee, M.-K. Evolving Treatment Landscape of Frontline Therapy for Metastatic Urothelial Carcinoma: Current Insights and Future Perspectives. Cancers 2024, 16, 4078. Cancers, 17(13), 2097. https://doi.org/10.3390/cancers17132097

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Article metric data becomes available approximately 24 hours after publication online.
Back to TopTop